UroGen Pharma Ltd. 8-K

What Happened
UroGen Pharma Ltd. announced the results of its 2026 Annual Meeting of Shareholders held on June 22, 2026. Shareholders approved an Amended and Restated Articles of Association that, among other changes, ties eligibility for shareholder proposals to the requirements of the Israeli Companies Law. The board had previously approved these amendments on March 19, 2026. Shareholders also approved an amendment to the company’s non-employee director and officer compensation policy relating to directors’ and officers’ insurance and approved an amendment to the 2017 Equity Incentive Plan to add 1,000,000 ordinary shares authorized for issuance.

Key Details

• Annual Meeting date: June 22, 2026. Board previously approved related amendments on March 19, 2026.
• Amended Articles (Proposal 2) approved: 19,306,222 votes for; 9,007,528 against; 22,274 abstentions; 8,540,308 broker non-votes.
• Compensation Policy Amendment (Proposal 3) approved: 26,089,418 for; 2,182,017 against; 64,589 abstentions; 8,540,308 broker non-votes. (Amends D&O insurance provisions.)
• 2017 Equity Incentive Plan increase (Proposal 4) approved: 25,204,644 for; 3,058,912 against; 72,468 abstentions; 8,540,308 broker non-votes. (Adds 1,000,000 shares.)
• Advisory vote on named executive officer compensation (Proposal 5) approved: 25,125,846 for; 3,186,040 against; 24,138 abstentions; 8,540,308 broker non-votes.
• Auditor engagement (Proposal 6) approved: PricewaterhouseCoopers LLP engaged — 36,778,509 for; 90,799 against; 7,024 abstentions (no broker non-votes on this item).
• Directors elected (Proposal 1): seven directors re-elected to serve until the next annual meeting. Vote tallies:
  • Arie Belldegrun, M.D.: 23,369,726 for; 4,959,968 against; 6,330 abstain; 8,540,308 broker non-votes.
  • Elizabeth Barrett: 25,942,072 for; 2,389,232 against; 4,720 abstain; 8,540,308 broker non-votes.
  • Cynthia M. Butitta: 26,378,838 for; 1,940,273 against; 16,913 abstain; 8,540,308 broker non-votes.
  • Stuart Holden, M.D.: 26,641,539 for; 1,687,876 against; 6,609 abstain; 8,540,308 broker non-votes.
  • James A. Robinson, Jr.: 27,918,601 for; 407,390 against; 10,033 abstain; 8,540,308 broker non-votes.
  • Leana S. Wen, M.D., M.Sc.: 26,667,146 for; 1,652,270 against; 16,608 abstain; 8,540,308 broker non-votes.
  • Daniel G. Wildman: 27,862,621 for; 453,366 against; 20,037 abstain; 8,540,308 broker non-votes.

Why It Matters
These votes enact governance and compensation changes that affect shareholder rights and potential dilution. Tying shareholder-proposal eligibility to the Israeli Companies Law could change which proposals qualify for inclusion in future shareholder meetings. The 1,000,000-share increase to the equity incentive plan expands the pool available for grants, which may dilute existing holders over time as awards vest or are exercised. The compensation policy amendment clarifies insurance coverage for directors and officers. Reappointment of PwC as auditor and the re-election of the board provide continuity in oversight and governance. Investors should note the vote margins and the sizable broker non-vote count on several items when assessing shareholder sentiment.